AR076542A1 - ISONICOTINAMIDE OREXINE RECEIVER ANTAGONISTS - Google Patents

ISONICOTINAMIDE OREXINE RECEIVER ANTAGONISTS

Info

Publication number
AR076542A1
AR076542A1 ARP100101505A AR076542A1 AR 076542 A1 AR076542 A1 AR 076542A1 AR P100101505 A ARP100101505 A AR P100101505A AR 076542 A1 AR076542 A1 AR 076542A1
Authority
AR
Argentina
Prior art keywords
methyl
carboxamide
bipyridin
dimethoxypyridin
fluorophenyl
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR076542A1 publication Critical patent/AR076542A1/en

Links

Abstract

La presente se refiere a compuestos de isonicotinamida que son antagonistas de los receptores de orexina, y que son utiles en el tratamiento o prevencion de trastornos y enfermedades neurologicas y psiquiátricas en las que están implicados los receptores de orexina. La presente también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos y composiciones en la prevencion o tratamiento de dichas enfermedades en las que están implicados los receptores de orexina. Reivindicacion 1: Un compuesto que se selecciona entre el grupo que consiste en: N-[(5,6-dimetoxipiridin-2-il)metil]-6-(2-fluorofenil)-5'-metil-3,3'-bipiridin-5-carboxamida; N-(3,4-dimetoxibencil)-2,5bis(3,5-dimetilfenil)isonicotinamida; N-(3,4-dimetoxibencil)-6-(3,5-dimetilfenil)-3,3'-bipiridin-4-carboxamida; N(3,4-dimetoxibencil)-2-(3,5-dimetilfenil)-5-(1-metil-1H-pirazol-4-il)isonicotinamida; N-(3,4-dimetoxibencil)-5-metil-3,2',5',3ö-terpiridin-4'-carboxamida; 6-(3-cloro-5-metilfenil)-N-(3,4-dimetoxibencil)-3,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxipiridin-3-il)metil]-2-(3,5-dimetilfenil)-5-fenilisonicotinamida; 5ö-cloro-N-[(5,6-dimetoxipiridin-2-il)metil]-2,3':6',3ö-terpiridin-4'-carboxamida; N-[(5,6-dimetoxipirazin-2-il)metil]-5-(3-fluorofenil)-5'-metil-2,3'-bipiridin-4-carboxamida; N-(3-ciclopropil-4-metoxibencil)-5-(3-fluorofenil)-5'-metil-2,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxipiridin-2-il)metil]-5-(2-fluorofenil)-5'-metil-2,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxipiridin-2-il)metil]-5-(3-fluorofenil)-5'-metil-2,3'-bipiridin-4-carboxamida; 5-(3-fluorofenil)-N-[4-metoxi-3-(trifluorometil)bencil]-5'-metil-2,3'-bipiridin-4-carboxamida; N-(3-cloro-4-metoxibencil)-5-(3-fluorofenil)-5'-metil-2,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxipiridin-2-il)metil]-5'-metil-5-pirazin-2-il-2,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxi-2-piridinil)metil]-5'-metil-5-(1-pirrolidinil)-2,3'-bipiridin-4-carboxamida; 5-azetidin-1-il-N-[(5,6-dimetoxipiridin-2-il)metil]-5'-metil-2,3'-bipiridin-4-carboxamida; N-[(5,6-dimetoxipiridin-2-il)metil]-5'-metil-5-(1,3-tiazol-2-il)-2,3'-bipiridin-4-carboxamida; 5'-cloro.-N-[(5,6-dimetoxipiridin-2-iI)metil]-5-(1,3-tiazol-2-il)-2,3'-bipiridin-4-carboxamida; N-[(5-ciclopropil-6-metoxipiridin-2-il)metil]-5'-metil-5-(1,3-tiazol-2-il)-2,3'-bipiridin-4- carboxamida; N-(3-cloro-4-metoxibencil)-5'-metil-5-(5-metil-1,3-tiazol-2-il)-2,3'-bipiridin-4-carboxamida; N-(3-etil-4-metoxibencil)-5'-metil-5-(4-metil-1,3-tiazol-2-il)-2,3'-bipiridin-4-carboxamida; o una sal farmacéuticamente aceptable de los mismos.This refers to isonicotinamide compounds that are antagonists of orexin receptors, and that are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. This also refers to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of said diseases in which orexin receptors are involved. Claim 1: A compound selected from the group consisting of: N - [(5,6-dimethoxypyridin-2-yl) methyl] -6- (2-fluorophenyl) -5'-methyl-3,3'- bipyridin-5-carboxamide; N- (3,4-dimethoxybenzyl) -2,5bis (3,5-dimethylphenyl) isonicotinamide; N- (3,4-dimethoxybenzyl) -6- (3,5-dimethylphenyl) -3,3'-bipyridin-4-carboxamide; N (3,4-dimethoxybenzyl) -2- (3,5-dimethylphenyl) -5- (1-methyl-1 H -pyrazol-4-yl) isonicotinamide; N- (3,4-dimethoxybenzyl) -5-methyl-3,2 ', 5', 3ö-terpyridin-4'-carboxamide; 6- (3-Chloro-5-methylphenyl) -N- (3,4-dimethoxybenzyl) -3,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxypyridin-3-yl) methyl] -2- (3,5-dimethylphenyl) -5-phenylisonicotinamide; 5ö-Chloro-N - [(5,6-dimethoxypyridin-2-yl) methyl] -2,3 ': 6', 3ö-terpyridin-4'-carboxamide; N - [(5,6-dimethoxypyrazin-2-yl) methyl] -5- (3-fluorophenyl) -5'-methyl-2,3'-bipyridine-4-carboxamide; N- (3-cyclopropyl-4-methoxybenzyl) -5- (3-fluorophenyl) -5'-methyl-2,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxypyridin-2-yl) methyl] -5- (2-fluorophenyl) -5'-methyl-2,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxypyridin-2-yl) methyl] -5- (3-fluorophenyl) -5'-methyl-2,3'-bipyridin-4-carboxamide; 5- (3-fluorophenyl) -N- [4-methoxy-3- (trifluoromethyl) benzyl] -5'-methyl-2,3'-bipyridin-4-carboxamide; N- (3-Chloro-4-methoxybenzyl) -5- (3-fluorophenyl) -5'-methyl-2,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxypyridin-2-yl) methyl] -5'-methyl-5-pyrazin-2-yl-2,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxy-2-pyridinyl) methyl] -5'-methyl-5- (1-pyrrolidinyl) -2,3'-bipyridin-4-carboxamide; 5-azetidin-1-yl-N - [(5,6-dimethoxypyridin-2-yl) methyl] -5'-methyl-2,3'-bipyridin-4-carboxamide; N - [(5,6-dimethoxypyridin-2-yl) methyl] -5'-methyl-5- (1,3-thiazol-2-yl) -2,3'-bipyridin-4-carboxamide; 5'-Chloro.-N - [(5,6-dimethoxypyridin-2-iI) methyl] -5- (1,3-thiazol-2-yl) -2,3'-bipyridin-4-carboxamide; N - [(5-cyclopropyl-6-methoxypyridin-2-yl) methyl] -5'-methyl-5- (1,3-thiazol-2-yl) -2,3'-bipyridine-4-carboxamide; N- (3-Chloro-4-methoxybenzyl) -5'-methyl-5- (5-methyl-1,3-thiazol-2-yl) -2,3'-bipyridin-4-carboxamide; N- (3-ethyl-4-methoxybenzyl) -5'-methyl-5- (4-methyl-1,3-thiazol-2-yl) -2,3'-bipyridin-4-carboxamide; or a pharmaceutically acceptable salt thereof.

ARP100101505 2009-05-22 2010-05-04 ISONICOTINAMIDE OREXINE RECEIVER ANTAGONISTS AR076542A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18057409P 2009-05-22 2009-05-22

Publications (1)

Publication Number Publication Date
AR076542A1 true AR076542A1 (en) 2011-06-22

Family

ID=44581604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101505 AR076542A1 (en) 2009-05-22 2010-05-04 ISONICOTINAMIDE OREXINE RECEIVER ANTAGONISTS

Country Status (2)

Country Link
AR (1) AR076542A1 (en)
TW (1) TW201043614A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225921A (en) * 2017-10-24 2020-06-02 拜耳股份公司 Prodrugs of substituted triazole derivatives and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225921A (en) * 2017-10-24 2020-06-02 拜耳股份公司 Prodrugs of substituted triazole derivatives and uses thereof

Also Published As

Publication number Publication date
TW201043614A (en) 2010-12-16

Similar Documents

Publication Publication Date Title
JP2012507538A5 (en)
NZ592544A (en) Isonicotinamide orexin receptor antagonists
PE20210128A1 (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THEM
RU2018123779A (en) New connections
CL2015000578A1 (en) Compound n- (2- (6-fluoro-1-h-indol-3-yl) ethyl) -3- (2,2,3,3-tetrafluoropropoxy) benzylamine or its salt, 5-ht6 receptor antagonist; pharmaceutical composition; Use in the treatment of Alzheimer's disease.
PE20180501A1 (en) BICYCLE BEDS AND METHODS OF USING THEM
PE20191499A1 (en) IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES
RU2011108281A (en) TRIPYRIDYL CARBOXAMIDE ANTAGONISTS OF OREXIN RECEPTORS
CL2004000234A1 (en) DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
CR9304A (en) GLUCAGON RECEIVER ANTAGONISTS, PREPARATIONS AND THERAPEUTIC USES
ES2337596T3 (en) ANTIGONISTS OF THE RECEIVER OF GLUCATION, PREPARATION AND THERAPEUTIC USES.
JP2007513915A5 (en)
CL2013003816A1 (en) Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases.
HRP20120918T1 (en) Amino pyrazole compound
JP2009523760A5 (en)
HRP20141116T1 (en) 1h-quinazoline-2,4-diones
MA29339B1 (en) FUSED THIAZOLE DERIVATIVES WITH AFFINITY FOR HISTAMINE H3 RECEPTOR
RU2017116196A (en) 2-amino-6- (difluoromethyl) -5,5-difluor-6-phenyl-3,4,5,6-tetrahydropyridines as bac1 inhibitors
RU2017123170A (en) HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION
RU2016116775A (en) 4-azaindole derivatives
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
JP2020502230A5 (en)
JP2017526724A5 (en)
JP2008516959A5 (en)
MA28238A1 (en) 1,4-DIAZABICYCLO [3.2.1] OCTANECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal